OasisLMS

Upon successful completion of The Kidney in Cardiometabolic Disease session, participants should be better able to:

• Analyze the kidney's role in cardiometabolic diseases such as diabetes, heart failure, atherosclerotic cardiovascular disease, mineral and bone disorders, and diseases that affect renal function.
• Distinguish the effects of decreased kidney function due to aging.

This activity is intended for Endocrinologists, along with the broader endocrine care team, including nurses, nurse practitioners (NPs), physician assistants (PAs), and diabetologists, play a vital role in ensuring that patients with kidney disease receive comprehensive and effective care. Their responsibilities include diagnosing, monitoring, and managing kidney disease, prescribing and adjusting medications, managing complications and comorbidities, educating patients, and guiding primary care professionals in kidney
disease management.

Healthcare professionals (HCPs), including family and internal medicine physicians, nurses, NPs, and PAs, are essential in delivering holistic, patient-centered care to individuals with kidney disease. They often establish long-term relationships with their patients, see them more frequently than specialists, and serve as the frontline in identifying and managing chronic disease risk factors.

There are almost 47.7 million individuals affected by chronic kidney disease (CKD) and about 28.6 million persons diagnosed with CVD. Moreover, more than 38 million people have diabetes (11.6% of the U.S. population), 90% of whom have type 2 diabetes (T2D). By 2045, the International Diabetes Federation projections show that approximately 783 million adults in the U.S. will be living with diabetes, an increase of 46%. These three entities are the major pandemics of the twenty-first century for the U.S.

Physician Credit
The American College of Endocrinology (ACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American College of Endocrinology (ACE) designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Only those who receive a passing score will be eligible for MOC credit.   Please allow two weeks for MOC points to appear within your account on the ABIM website. Participation information will be shared.  

Physician Credit

Provider approved by the California Board of Registered Nursing, Provider Number 17762, for 1 contact hours.

Disclosure and Conflicts of Interest Policy: The American Association of Clinical Endocrinologists (AACE) remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of AACE to eliminate all situations of potential conflict of interest, but rather to enable those who are working with AACE to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the CME Subcommittee to ensure that such situations are properly evaluated and, if necessary, resolved. AACE educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all AACE accredited activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities. 

Planning Committee Disclosures

Planner Disclosures:

Planner Name	Ineligible Company	Relevant Financial Relationship
Diana Isaacs	(1) Abbott, Dexcom, Medtronic, Insulet, Lilly, Novo Nordisk, Cequr, Sanofi (2) Lilly, Sanofi, Medtronic, Lifescan, Sequel	(1) Speakers Bureau (2) Advisory Board
Anupam Kotwal	Interpace Diagnostica	Consultant
Cecilia Low Wang	Dexcom, Virta Health	Research Funding
Archana Sadhu	Abbott	Consultant
Rifka Schulman-Rosenbaum, MD	Sanofi	Publication Support

All of the relevant financial relationships listed for these individuals have been mitigated. All other planners for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.

Faculty Disclosures

Faculty Disclosures:

Planner Name	Ineligible Company	Relevant Financial Relationship
Lance Sloan	(1) NovoNordisk, Merck, Amgen, Janssen, BI, Lilly, Corcept, Sanofi  (2) Corcept, Pfizer, NovoNordisk, Bayer, Insorsia; Speaker bureau with Boehringer Ingelheim, Lilly, Corcept, Sanofi, Bayer, Astra Zeneca, Pfizer, Madrigal, Xeris (3) NovoNordisk, Merck, Amgen, Janssen, BI, Lilly, Corcept, Sanofi (4) BI, Lilly, Bayer, Pfizer, Corcept, Sanofi, Xeris (5) BI, Novo Nordisk, Bayer, Corcept, Idorsia	(1) Principal investigator for pharmaceutical trials; (2) Advisory Board (3) Principal investigator for pharmaceutical trials (4) Speakers Bureau (5) Consultant

All of the relevant financial relationships listed for these individuals have been mitigated. All other faculty for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.

Reviewer Disclosures

All of the relevant financial relationships listed for these individuals have been mitigated. All other reviewers for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.

@AACE 2025